Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jacqueline Vanderpuye-Orgle
Observed names:
J Vanderpuye-Orgle,
J. Vanderpuye-Orgle,
Jackie Vanderpuye-Orgle,
Jacqueline Vanderpuye‐Orgle
Observed institutions:
Amgen (United States),
PAREXEL International (United Kingdom),
Cornell University,
PAREXEL International (United States),
Analysis Group (United States)
ORCID:
0000-0002-4533-1298
Observed ORCID:
0000-0002-4533-1298
OpenAlex ID:
A5008133506
Healthcare Policy Changes in Osteoporosis Can Improve Outcomes and Reduce Costs in the United States
2019
·
E Michael Lewiecki
, Jesse D Ortendahl
, et al.
·
JBMR Plus
·
249
PDF
Evaluating the economic burden of psoriasis in the United States
2015
·
Jacqueline Vanderpuye-Orgle
, Yang Zhao
, et al.
·
Journal of the American Academy of Dermatology
·
171
Risk Management and Social Visibility in Ghana*
2009
·
Jacqueline Vanderpuye‐Orgle
, Christopher B. Barrett
·
African Development Review
·
34
Impact of Oral Nutrition Supplements on Hospital Outcomes in Pediatric Patients
2014
·
Darius N. Lakdawalla
, Maria Mascarenhas
, et al.
·
Journal of Parenteral and Enteral Nutrition
·
33
HIV Care Providers Emphasize The Importance Of The Ryan White Program For Access To And Quality Of Care
2014
·
Neeraj Sood
, Timothy Juday
, et al.
·
Health Affairs
·
33
Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature
2017
·
Nicholas Summers
, Jacqueline Vanderpuye-Orgle
, et al.
·
Current Medical Research and Opinion
·
22
Estimating the social value of G-CSF therapies in the United States.
2016
·
Jacqueline Vanderpuye-Orgle
, Alison Sexton Ward
, et al.
·
PubMed
·
15
Competition in the Age of Biosimilars
2015
·
Amitabh Chandra
, Jacqueline Vanderpuye-Orgle
·
JAMA
·
15
Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up
2022
·
M. A. Chaudhary
, M. Edmondson-Jones
, et al.
·
Medical Decision Making
·
14
PDF
Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials
2024
·
Jeffrey S. Weber
, Mark R. Middleton
, et al.
·
Journal of Clinical Oncology
·
11
PDF
Risk Prediction Using Bayesian Networks: An Immunotherapy Case Study in Patients With Metastatic Renal Cell Carcinoma
2021
·
Alind Gupta
, Paul Arora
, et al.
·
JCO Clinical Cancer Informatics
·
10
Ai3 Prediction of Breast Cancer Using K-nearest Neighbour: a Supervised Machine Learning Algorithm
2020
·
S. Pandey
, A. Sharma
, et al.
·
Value in Health
·
4
The relationship between adherence and total spending among Medicare beneficiaries with type 2 diabetes.
2017
·
Joanna P MacEwan
, John J Sheehan
, et al.
·
PubMed
·
4
Public-Private Partnership as a Path to Affordable Healthcare in Emerging Markets
2015
·
Jacquelyn W. Chou
, Darius N. Lakdawalla
, et al.
·
Forum for Health Economics & Policy
·
4
Understanding price growth in the market for targeted oncology therapies.
2019
·
Jesse Sussell
, Jacqueline Vanderpuye-Orgle
, et al.
·
PubMed
·
3
Product naming, pricing, and market uptake of biosimilars
2015
·
Joseph P Fuhr
, Amitabh Chandra
, et al.
·
Generics and Biosimilars Initiative Journal
·
3
PDF
MSR110 The Use of Artificial Intelligence for the Development of Health Economic Models
2023
·
J.E. Poirrier
, K. Kolasa
, et al.
·
Value in Health
·
2
PDF
PT7 Selection and Stability of Parametric Bivariate Copula Models for Joint Modelling of Overall and Progression-Free Survival
2025
·
Daniel J. Sharpe
, Ashley E. Tate
, et al.
·
Value in Health
·
1
MSR67 Modelling the Patient-Level Dependence of Overall Survival on Time to Objective Response in Oncology Studies Using Copulas
2024
·
DJ Sharpe
, AE Tate
, et al.
·
Value in Health
·
1
EE300 Looking Sharp! Applying Cutting-Edge Shapley Additive Explanation (SHAP) Approaches to Cost-Effectiveness Modelling in Contrast to One-Way Sensitivity Analysis
2023
·
S. Perni
, J. Vanderpuye-Orgle
, et al.
·
Value in Health
·
1
PDF
POSC77 Incorporating Possibility of Cure into Cost Utility Analysis for Nivolumab in Adjuvant Treatment of Resected Stage III/IV Melanoma in France
2022
·
G Harris
, I Orsini
, et al.
·
Value in Health
·
1
Pcn264 Estimating the Burden of Salivary Gland Cancer in Nordic Countries: a Predictive Analysis Using Time Series Analysis Methods
2019
·
S. Pandey
, M.K. Siddiqui
, et al.
·
Value in Health
·
1
PDF
Reconsidering the economic impact of the EU manufacturing and export provisions
2017
·
Jesse A Sussell
, Mahlet G Tebeka
, et al.
·
Journal of Generic Medicines The Business Journal for the Generic Medicines Sector
·
1
Does patient cost sharing for HCV drugs make sense?
2016
·
Darius N Lakdawalla
, Mark T Linthicum
, et al.
·
PubMed
·
1
Bayesian Evidence Synthesis for Indirect Treatment Comparisons of Extrapolated Survival Outcomes Leveraging Historical Trial Data
2026
·
Daniel J. Sharpe
, Ashley E. Tate
, et al.
·
Medical Decision Making
PDF
Show more works
View as search
Works count:
59
Citation count:
634
H-index:
10
I10-index:
11
Year
Topic
Type
